Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer
Status:
Completed
Trial end date:
2017-01-22
Target enrollment:
Participant gender:
Summary
This is a Phase II open study, not randomized with a neoadjuvant therapy,combination of
Gemcitabine (1,000 mg/m2/week) with Erlotinib (100mg/day) (3 cycles of 4 weeks), followed by
gemcitabine (300 mg/m2/week) combined with Erlotinib (100mg/day) and radiotherapy (45 Gy /
day fr180 cGy) (5 cycles of 1 week) in patients with resectable pancreatic adenocarcinoma to
assess the percentage of R0 resections. They have planned a total of 21 visits.
Phase:
Phase 2
Details
Lead Sponsor:
Grupo Espanol Multidisciplinario del Cancer Digestivo